FDA Investigator Linda S Leja
Linda S Leja has conducted inspections on 44 sites in 9 countries as of 25 Jun 2024. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
44
Last Inspection Date:
25 Jun 2024
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America,
Canada,
Denmark,
Germany,
Italy,
Czechia,
Russian Federation,
Netherlands,
Switzerland
FDA Investigators that have inspected at least one site in common with Linda S Leja:
Andrew K Haack, PhD,
Andrew R Wasko,
Anita Narula, PhD,
Astrida B Mattson,
Barbara Janine Breithaupt,
Brenda L Reihing,
Carl A Anderson,
Charles R Bonapace, PhD,
Connie P Rezendes,
Ct Viswanathan, PhD,
Cynthia L Gorveatt,
Dawn E Barkans,
Dolores E Price,
Donald B Mckechnie,
Dov H Pluznik, PhD,
Dr. Mark J Seaton, PhD,
Dr. Zhou Chen (nmi), MD PhD,
Dylan D Yao, MD, PhD,
Erin M Mcdowell,
Gajendiran Mahadevan, PhD,
Gloria J Baca, MS,
Grace P Santos,
Heika R Bounds,
Heika R Tait,
Hugh M Mcclure, II,
Jacqueline A O'shaughnessy, PhD,
James M Kewley,
Jane M Kreis,
John A Iwen,
Joseph P Iser, MD,
Julia E Chervoni,
Julian C Hanson,
June H Wetherington,
Kathryn A Krentz,
Lawrence Y Lee, PhD,
Lisa K Capron,
Lori J Silverstein,
Maria Pkelly Doggett, MBA,
Marijo B Kambere, PhD,
Mark W Babbitt,
Michael C Rogers,
Michael F Skelly, PhD,
Mikel T Wright,
Mohsen Rajabi Abhari, FDA,
Nancy A Saxenian Emmons,
Nancy E Byerly,
Paul M Kawamoto,
Paula A Trost,
Randy L Self,
Richard S Andros,
Robert C Coleman,
Robert C Steyert,
Robert D Tollefsen,
Rocco C Black,
S Lori Brown, PhD MPH,
Sangeeta M Khurana, PhD,
Sharon I Gundersen,
Sherri N Rohlf, MD,
Sripal R Mada, PhD,
Stanley B Eugene, BS, BME,
Stephanie A Slater, MS,
Sunitha K Rajaram, PhD,
Susan D Yuscius,
Susan E Molchan, MD,
Susan T Hadman,
Terri L Dodds,
Vanessa Y Gelsey, PhD,
Veronica L Bush,
Virgilio F Pacio, CSO,
Xikui Chen (nmi), PhD
Linda S Leja's Documents
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more